Gluconorm Vg-1 Forte Tab

Tablet

Type 2 diabetes mellitus (adult) to improve blood glucose control when diet and exercise alone are not sufficient; used when combination therapy with metformin, a DPP-4 inhibitor and a sulfonylurea is appropriate.

Metformin reduces glucose production in the liver and improves insulin sensitivity. Vildagliptin (a DPP-4 inhibitor) increases incretin hormones, enhancing glucose-dependent insulin release and reducing glucagon. Glimepiride (a sulfonylurea) stimulates insulin release from pancreatic beta cells to lower blood glucose.

Take orally exactly as prescribed, usually once daily with food (preferably with the main meal) to reduce stomach upset and hypoglycaemia risk. Swallow whole; do not crush/chew (especially if sustained/extended release). Monitor blood glucose regularly; follow diet and exercise advice.

Hypoglycaemia, nausea, vomiting, diarrhoea, abdominal discomfort, loss of appetite, headache, dizziness, weight gain, metallic taste

Risk of hypoglycaemia (higher with glimepiride): carry glucose and avoid skipping meals. Metformin may rarely cause lactic acidosis—seek urgent care for rapid breathing, severe weakness, abdominal pain, or unusual sleepiness; higher risk with kidney disease, dehydration, severe infection, alcohol use. Monitor kidney function before and during therapy; avoid in severe renal impairment. Vildagliptin may affect liver enzymes—periodic LFT monitoring recommended; stop and consult doctor if jaundice or persistent nausea occurs. Use caution in elderly, malnourished, or those with adrenal/pituitary insufficiency. Inform doctor before surgery or iodinated contrast imaging; metformin may need temporary discontinuation. Not for type 1 diabetes or diabetic ketoacidosis.

Alcohol (increases lactic acidosis and hypoglycaemia risk), iodinated contrast media, insulin/other antidiabetics (additive hypoglycaemia), sulfonylureas with beta-blockers (mask hypoglycaemia), corticosteroids/thiazide diuretics (raise glucose), ACE inhibitors (may increase hypoglycaemia risk), cimetidine and other drugs affecting renal tubular secretion (increase metformin levels), strong CYP2C9 inhibitors/inducers affecting glimepiride (e.g., fluconazole, rifampicin)

Store below 25°C in a cool, dry place. Protect from moisture and light. Keep out of reach of children.

Glycomet-GP 1 + Galvus 50 (equivalent regimen), Istamet-GP 1 Forte (similar triple therapy), Zomelis-GP 1 Forte (similar triple therapy), Jalra-M GP 1 Forte (similar triple therapy), Vogli-MP 1 (alternative combination; composition differs)